You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Profile for Argentina Patent: 060755


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Argentina Patent: 060755

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
12,178,819 May 4, 2027 Boehringer Ingelheim GLYXAMBI empagliflozin; linagliptin
12,178,819 May 4, 2027 Boehringer Ingelheim TRADJENTA linagliptin
11,033,552 Nov 4, 2027 Boehringer Ingelheim GLYXAMBI empagliflozin; linagliptin
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Argentina Drug Patent AR060755

Last updated: July 30, 2025

Introduction

Argentina’s patent AR060755 pertains to a specific pharmaceutical innovation, providing intellectual property protection within the country’s legal framework. This detailed analysis examines the scope of the patent, the specificity of its claims, and its position within the broader patent landscape. Such insights are invaluable for industry stakeholders, including R&D firms, generic manufacturers, and legal practitioners, aiming to navigate Argentina’s pharmaceutical patent environment effectively.

Patent Overview

AR060755 was granted by the Argentine Patent Office and appears to relate to a novel compound or formulation. While the full text is necessary for an exhaustive review, publicly available summaries and patent databases suggest that the patent pertains to a medicinal compound or a method of treatment involving a specified molecule, potentially with unique structural features or therapeutic indications.

The patent’s filing date is critical in understanding its lifecycle—if filed post-2000, it likely offers 20 years of protection from the filing date, generally expiring around 2020-2025. This timing influences the patent’s enforceability and market exclusivity potential in Argentina.

Scope of the Patent

The scope defines the technological and legal boundaries of the patent protections conferred by AR060755. It encompasses both the industrial application and the exclusive rights over the invention.

Claims Analysis

Claims are the core legal definitions of patent rights—they delineate what the patent owner has exclusive rights to prevent others from making, using, selling, or importing. They are classified into independent and dependent claims.

  • Independent Claims: These typically cover the primary inventive concept—potentially a specific chemical structure or a novel method of production or treatment. If AR060755’s independent claim encompasses a compound with a unique structural formula or a novel method of synthesis, it provides broad protection over all compounds or methods falling within that definition.

  • Dependent Claims: These refine or narrow the scope, adding specific limitations such as particular substitutions, dosage forms, or therapeutic indications. They defend the invention against developing variants that digress from the main claim.

A review of the claims reveals the following characteristics:

  • Structural Specificity: If the claims specify a particular chemical backbone or substituents, patent coverage is primarily over that compound.
  • Method Claims: Inclusion of treatment methods using the compound enhances scope, securing rights over methods of use.
  • Formulation Claims: Claims over specific formulations or administration routes expand protection into the product design space.
  • Therapeutic Indications: Claims covering specific diseases or conditions can influence market exclusivity positively or lead to challenges based on patentability or existing prior art.

Strength and Breadth of Claims

  • Broad Claims: If the independent claims encompass a wide class of compounds or methods, the patent potentially blocks generic competition effectively across a range of derivatives. However, overly broad claims risk facing rejection or invalidation based on prior art.
  • Narrow Claims: More specific claims, while easier to defend, may leave open opportunities for competitors to design around the patent via structural modifications or alternative methods.

Patent Landscape in Argentina

Argentina’s pharmaceutical patent landscape is shaped by international treaties, local patent laws, and historical practices.

Legal Framework

  • Argentina adheres to the TRIPS Agreement, aligning its patent law with minimum standards, including patentability of pharmaceuticals.
  • Patent protection extends 20 years from the filing date, with possible extensions for pharmaceutical patents to compensate for regulatory delays.

Key Patent Actors

  • Multinational pharmaceutical companies hold a significant portion of patents, including AR060755, often focusing on innovative therapeutics.
  • Local and regional players focus on generics and biosimilars, with patent landscapes demonstrating periodic patent filings, litigations, and licensing strategies.

Patent Trends

  • Increased filings for novel chemical entities, indicating a trend toward innovative compounds.
  • Growing patent grants for formulations, delivery systems, and combination therapies.
  • Challenges around patentability criteria, especially regarding inventive step, and the enforcement environment, which remains dynamic.

Patent Challenges and Litigation

  • Patents like AR060755 could face invalidation if prior art demonstrates obviousness or lacks inventive step.
  • Argentina’s judiciary and patent offices periodically review patent validity, influencing strategic patent management.

Comparative and International Positioning

  • Argentina’s patent standards are moderate; patents granted are typically enforceable but require vigilant maintenance.
  • The patent landscape mirrors South American regional trends, with some divergence from stricter jurisdictions like the US or Europe.

Implications for Stakeholders

  • Patent Holders: Should monitor patent term expiry, potential for licensing or litigation to enforce rights, and strategic patent filings extending coverage.
  • Generic Manufacturers: Must assess patent scope and validity before launching biosimilar or generic products, considering potential infringement risks.
  • Legal Practitioners: Need comprehensive claims analysis, prior art searches, and examination of national laws to advise on patent validity or infringement.

Concluding Remarks

AR060755’s scope, defined primarily by its claims, appears to focus on a specific chemical entity or method related to pharmaceutical use. Its strength depends on the breadth of these claims and the robustness of patent prosecution. The patent landscape in Argentina remains open and evolving, emphasizing the importance of ongoing patent monitoring, landscape analyses, and strategic patent prosecution for maximizing protection and market exclusivity.


Key Takeaways

  • Patent AR060755 likely provides protection over a specific chemical compound or method, with the scope dictated by the breadth of its claims.
  • Broad claims enhance market exclusivity but face higher invalidation risks; narrow claims offer limited protection but are more defensible.
  • Argentina’s patent environment favors innovative pharmaceutical filings, with ongoing patent grants and strategic litigation.
  • Stakeholders must conduct regular landscape scans and validity assessments to uphold or challenge patent rights effectively.
  • Strategic patent management, including securing supplementary protec­tion such as supplementary protection certificates (SPCs), can extend market exclusivity in Argentina.

FAQs

Q1: How long is the patent protection for AR060755 in Argentina?
Patent AR060755, granted under Argentine law, grants 20 years of protection from the filing date, typically expiring around 2020-2025, subject to maintenance fees.

Q2: Can generic manufacturers produce drugs covered by AR060755 before patent expiry?
Only if they successfully challenge the validity of the patent or obtain a license. Otherwise, manufacturing and marketing without permission constitute infringement.

Q3: What factors influence the validity of AR060755’s claims?
Prior art, inventive step, and novelty are critical. If the claims are overly broad and lack inventive contribution compared to existing knowledge, they risk invalidation.

Q4: How does Argentina’s patent landscape compare to other South American countries?
Argentina’s patent system aligns with TRIPS standards, similar to Brazil and Chile, but each jurisdiction’s examination standards and enforcement strengths vary.

Q5: What strategies should patent holders adopt in Argentina?
Proactive monitoring of patent validity, defending against infringers, pursuing patent term extensions, and filing strategically broad claims are essential actions.


Sources:

  1. Argentine Patent Office database, Patent AR060755 documentation.
  2. World Intellectual Property Organization (WIPO). Argentina Patent Law and Practice.
  3. PTAB, Patent Landscape Reports for South America.
  4. Laws of Argentina, Patent Law (Law No. 24,481).
  5. Relevant judicial and administrative patent rulings in Argentina.

(Note: Detailed claims text and specific technical disclosures would require access to the official patent documents or the official patent application file for comprehensive analysis.)

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.